Ultime notizie per AngioDynamics (NASDAQ:ANGO) Azioni

AngioDynamics

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

AngioDynamics Inc

ANGO WORLD HOLDINGS INC by ANGO World Holdings, Inc.

Angold Resources Ltd Ordinary Shares

HC Wainwright &amp; Co. analyst Yi Chen reiterates AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and maintains $14 price target.

News

Price Target

Reiteration

Analyst Ratings

ANGO

HC Wainwright & Co. Reiterates Buy on AngioDynamics, Maintains $14 Price Target

Biotech

General

AngioDynamics Initiates RECOVER-AV Clinical Trial Of AlphaVac F18⁸⁵ System In Pulmonary Embolism And Long-Term Functional Outcomes

AngioDynamics Announces CE Mark Approval For Auryon System In Europe

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Monday.
Shares of PDD Holdings Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/08/40548945/temu-parent-pdd-posts-86-q2-topline-growth-stock-drops-after-ceo-flags-upcoming-challenges">second-quarter revenue miss.</a>
PDD reported fiscal second-quarter 2024 revenue growth of 86% year-on-year to $13.36 billion (97.06 billion Chinese yuan), missing the analyst consensus estimate of $14.02 billion. The Chinese online retailer's adjusted earnings per ADS of $3.20 (23.24 Chinese yuan) increased from 10.47 Chinese yuan Y/Y, beating the analyst consensus estimate of $2.73.
PDD shares dipped 15.2% to $118.65 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>SM Energy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>) fell 7.5% to $42.42 in pre-market trading after gaining over 3% on Friday.</li>
<li>Westlake Chemical Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) shares dipped 5.4% to $21.50 in pre-market trading.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares fell 5.1% to $7.29 in pre-market trading.</li>
<li>Daqo New Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares declined 5.1% to $14.43 in pre-market trading after reporting downbeat quarterly results.</li>
<li>Yiren Digital Ltd &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) shares fell 4.6% to $4.63 in pre-market trading.</li>
<li>elf Beauty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) shares declined 3.8% to $164.50 in pre-market trading.</li>
<li>Guardant Health Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) shares fell 3% to $28.20 in pre-market trading after gaining 4% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40547904/pvh-likely-to-report-higher-q2-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earn">PVH Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

Citigourp Global Markets 2% Protected Notes Linked To The Djia

WLKP

PDD Holdings, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Accuray Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aray#NASDAQ">ARAY</a>) and Halifax Health announced a breakthrough in cancer treatment at the Charles L. and Miki N. Grant Cancer Center for Hope in Port Orange, FL. The center&#39;s medical team became the first in the United States to treat cancer patients using Accuray&#39;s Radixact System with VitalHold technology. This innovative system is designed to enhance the precision of radiation therapy by improving patient positioning and monitoring throughout the treatment process, offering a new standard of care for a wide range of cancer cases, including breast cancer.
<h3>Significance of Radixact</h3>
Per Accuray, Radixact System, backed by VitalHold and other advanced technologies like ClearRT helical CT imaging and Synchrony real-time adaptive delivery, represents a significant advancement in radiotherapy. VitalHold&#39;s surface-guided radiotherapy (SGRT) ensures accurate patient positioning, improving the reproducibility of treatments and enabling deep inspiration breath hold techniques. This minimizes radiation exposure to critical organs, reducing long-term complications. The system&#39;s tattoo-free positioning further enhances patient experience, making radiation therapy more comfortable and cosmetically appealing.
The anticipated 35% increase in new cancer cases in the United States by 2040 underscores the critical need for advanced resources. Accuray&#39;s Radixact System, equipped with the VitalHold feature, is designed to meet this challenge by providing precise, high-quality radiation therapy from simulation through delivery. Management highlighted the partnership with Halifax Health, where the first U.S. patients have been treated using this innovative system, as a testament to its commitment.
<h3>Industry Prospects</h3>
Per a report in Precedence Research, the global radiation therapy market size is expected to be worth $7.47 billion in 2024. It is anticipated to reach $16.30 billion by 2033 at a CAGR of 8.6%.
The robust growth will be primarily driven by the increasing incidence of cancer, leading to higher demand for radiation therapy. Additionally, advancements in radiation therapy technology, including enhanced ionizing radiation and improved efficiency in targeting cancerous cells, are boosting its effectiveness and utilization in oncology.
Growing awareness about the benefits of advanced radiation therapy, along with initiatives to educate the public, is also accelerating market growth. The integration of innovative features and software systems in radiation therapy will enhance performance, driving increased demand and market value during the forecast period.
In June, Accuray announced that Heidelberg University Hospital in Germany is set to adopt its Radixact System, replacing its older TomoTherapy System.
<h3>Other Industry Players</h3>
Some other companies from the Medical Instruments industry making notable developments in their respective businesses are AngioDynamics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ango#NASDAQ">ANGO</a>), Intuitive Surgical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) and Masimo Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/masi#NASDAQ">MASI</a>). 
AngioDynamics is a pioneering medical technology company dedicated to advancing vascular health and cancer treatment.
In May, AngioDynamics received European CE Mark approval for its AlphaVac F1885 System, which is designed for the non-surgical removal of thrombi from pulmonary arteries and the treatment of pulmonary embolism.
Intuitive Surgical is a global leader in minimally invasive care and a pioneer of robotic surgery. Known for its da Vinci surgical system and Ion endoluminal system, Intuitive combines cutting-edge technology, advanced learning and supportive services to help healthcare providers deliver optimized patient care.
In June, Intuitive Surgical received FDA clearance for a labeling revision of its da Vinci X and Xi robotic systems specifically for radical prostatectomy. This update reflects real-world evidence showing that long-term survival rates for patients undergoing robotic-assisted radical prostatectomy are comparable to those receiving non-robotic procedures.
Masimo&#39;s a global medical technology company specializing in advanced monitoring technologies, including pulse oximetry, sensors, patient monitors and connectivity solutions. Known for its Masimo SET pulse oximetry, which has been proven to outperform other technologies in over 100 studies, Masimo&#39;s innovations have improved patient outcomes, particularly in neonates and post-surgical care.
This month, the Masimo W1 medical watch received FDA 510(k) clearance for connectivity with the Masimo SafetyNet telemonitoring solution. This integration allows the Masimo W1 watch, which provides continuous oxygen saturation and pulse rate measurements, to seamlessly transmit data to the Masimo SafetyNet app and clinician portal. This enables remote caregivers, including hospital clinicians, to monitor patient data from anywhere.
<a href="https://www.zacks.com/stock/news/2322538/accuray-s-aray-radixact-for-cancer-treatment-debuts-in-us?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2322538">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Penny Stocks

Health Care

Small Cap

Management

ARAY

ISRG

MASI

Accuray's Radixact for Cancer Treatment Debuts in US

Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and lowers the price target from $18 to $13.

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $13

U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index surging more than 650 points on Tuesday.
The Dow traded up 1.63% to 40,865.59 while the NASDAQ fell 0.11% to 18,452.31. The S&amp;P 500 also rose, gaining, 0.37% to 5,652.28.
Check This Out: <a href="https://www.benzinga.com/news/24/07/39789748/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Industrials shares jumped by 2.3% on Tuesday.
In trading on Tuesday, information technology shares fell by 0.8%.
Top Headline
Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) reported better-than-expected second-quarter results.
Morgan Stanley reported second-quarter EPS of $1.82, up from $1.24 a year ago and beating the consensus of $1.65. The U.S. bank reported second-quarter sales of $15.02 billion, up 11.6% year over year, beating the consensus of $14.30 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares shot up 93% to $2.07 after the company obtained an exclusive global license to develop, manufacture, and commercialize its Alzheimer&#8217;s drug.</li>
<li>Shares of Yoshitsu Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) got a boost, surging 92% to $0.5884 after the company reported a year-over-year increase in FY24 financial results.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares were also up, gaining 25% to $7.40 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares dropped 8% to $67.39 after Loop Capital downgraded the stock from Buy to Hold.</li>
<li>Shares of The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) were down 9% to $68.55 following second-quarter results.</li>
<li>Clearmind Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) was down, falling 17% to $1.84. Clearmind Medicine announced the FDA clearance for IND application of MEAI-based CMND-100 oral capsule.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39789793/tecogen-and-3-other-stocks-under-5-insiders-are-buying">Tecogen And 3 Other Stocks Under $5 Insiders Are Buying</a>
Commodities In commodity news, oil traded down 1.3% to $80.82 while gold traded up 1.5% at $2,464.30.
Silver traded up 1.6% to $31.44 on Tuesday, while copper fell 1.7% to $4.4505.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.28%, Germany's DAX fell 0.39% and France's CAC 40 fell 0.69%. Spain's IBEX 35 Index fell 0.47%, while London's FTSE 100 fell 0.22%.
The ZEW Indicator of Economic Sentiment for the Eurozone fell by 7.6 points to a reading of 43.7 in July, while Eurozone posted a trade surplus of EUR 13.9 billion in May versus a year-ago gap of EUR 0.4 billion.
The ZEW Indicator of Economic Sentiment for Germany fell to 41.8 in July, recording the first decline in a year. Italy reported a trade surplus of EUR 6.43 billion in May versus a year-ago surplus of EUR 4.767 billion year.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.20%, Hong Kong's Hang Seng Index falling 1.60%, China's Shanghai Composite Index gaining 0.08% and India's S&amp;P BSE Sensex gaining 0.06%.
Economics
<ul>
<li>U.S. retail sales came in flat month-over-month for June compared to a revised 0.3% gain in the previous period.</li>
<li>Import prices came in unchanged from the prior month in June, while export prices in the U.S. declined 0.5% month-over-month in June.</li>
<li>The NAHB/Wells Fargo Housing Market Index fell by one point to a reading of 42 in July, versus market estimates of 44.</li>
<li>U.S. total business inventories increased by 0.5% month-over-month in May compared to a 0.3% gain in the earlier month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39769294/top-5-financials-stocks-that-may-collapse-this-month">Top 5 Financials Stocks That May Collapse This Month</a></li>
</ul>

Earnings

Eurozone

Commodities

Intraday Update

CMND

RDDT

SCHW

SILO

TKLF

Nasdaq Edges Lower; Morgan Stanley Earnings Top Views

Tuesday, AngioDynamics Inc&nbsp;(NASDAQ:&nbsp;ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.
Fourth-quarter sales totaled $70.98 million, beating the analyst consensus of $70.89 million, according to data from&nbsp;<a target="_blank" href="https://pro.benzinga.com/feature/newsfeed/?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348&amp;_gl=1&#x2A;1cdknur&#x2A;_ga&#x2A;Mjc5MjI1Mjg4LjE2OTcxMjgyNzY.&#x2A;_ga_V7ZK73W7N0&#x2A;MTY5ODk5Njg5OC4yNS4xLjE2OTg5OTcwMTAuMTcuMC4w" rel="noreferrer noopener">Benzinga Pro</a>.
Pro forma net sales rose 1.9% to $71.1 million. Med Tech segment net sales were $29.3 million, up 11.3% year over year.
Growth was driven by Auryon sales of $13.0 million, which increased 12.0%, NanoKnife disposable sales of $5.4 million, representing an increase of 18.0% compared to the fourth quarter of fiscal 2023, and AlphaVac sales of $1.9 million, an increase of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39788500/angiodynamics-reports-fiscal-year-2024-fourth-quarter-and-full-year-financial-results" rel="noreferrer noopener">6.8% over the prior year</a>.
Med Device net sales were $41.8 million, a decrease of 3.8% compared to $43.4 million in the prior-year period.
AngioDynamics also announced a stock repurchase program of up to $15.0 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38045727/angiodynamics-resolves-decade-long-patent-litigation-with-becton-dickinson-in-settlement-agreeme" rel="noreferrer noopener">AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement</a>.
&#8220;We view 2025 as an inflection point in the trajectory of our business&#8230;The increased scale of our Med Tech business, in combination with the optimization of our Med Device business, will allow us to begin to see increasing leverage as we exit the year. Operationally, we will continue to work through the transition of our manufacturing model to reduce overhead costs and improve margins in 2026 and beyond,&#8221; commented Jim Clemmer, President and CEO.
Guidance: AngioDynamics expects its fiscal year 2025 net sales of $282 million-$288 million, up 4.2%–6.4% year over year from 2024 pro forma revenue of $270.7 million and <a href="https://www.benzinga.com/calendars/guidance">compared to the consensus of $287.68 million.</a>
The outlook includes Med Tech net sales to increase 10%-12%, and Med Device net sales are expected to grow 1%-3%.
Gross margin is expected to be approximately 52% to 53% for fiscal year 2025. Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million a year ago.
AngioDynamics forecasts fiscal year 2025 adjusted EPS loss of $0.38-$0.42, compared to fiscal 2024 pro forma adjusted EPS loss of $0.45 and consensus loss of $0.49.
Price Action: ANGO shares are up 25.6% at $7.445 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39793333/morgan-stanley-q2-earnings-higher-profits-as-investment-banking-activity-rebounds-on-track-to-reach" target="_blank" rel="noreferrer noopener">Morgan Stanley Q2 Earnings: Higher Profits As Investment Banking Activity Rebounds, On Track To Reach $10T Client Assets</a>.</li>
</ul>

Equities

Guidance

Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance

Shares of The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) fell sharply during Tuesday's session following <a href="https://www.benzinga.com/quote/SCHW/earnings">second-quarter results.</a>
Charles Schwab said adjusted net income declined 2% Y/Y to $1.465 billion. Adjusted EPS fell 3% Y/Y to 73 cents, beating the consensus of 72 cents, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Charles Schwab shares dipped 7.5% to $69.42 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Yoshitsu Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) jumped 109% to $0.6437 after the company reported a year-over-year increase in FY24 financial results.</li>
<li>Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares climbed 95.4% to $2.12 after the company obtained an exclusive global license to develop, manufacture, and commercialize its Alzheimer&#8217;s drug.</li>
<li>Logistic Properties of the Americas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares climbed 53.8% to $23.71.</li>
<li>NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) gained 38% to $3.8503.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) gained 38% to $1.4799.</li>
<li>AEON Biopharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEON#NYSE">AEON</a>) shares rose 29.2% to $2.9450 after jumping around 63% on Monday.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) gained 27.3% to $0.3055 after declining over 8% on Monday.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) surged 24.7% to $7.39 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) gained 22.8% to $0.4160</li>
<li>Zenvia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENV#NASDAQ">ZENV</a>) climbed 22.7% to $1.9634. The company announced that it entered into an agreement with Alliance Global Partners to offer and sell Class A common shares up to $20 million.</li>
<li>Locafy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) rose 21% to $4.4150.</li>
<li>SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) gained 20% to $1.0150.</li>
<li>Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) rose 19.8% to $10.45.</li>
<li>Alpha Technology Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) climbed 19.2% to $3.42.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) shares rose 16.1% to $1.01 after surging around 15% on Monday.</li>
<li>NetSol Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTWK#NASDAQ">NTWK</a>) climbed 16% to $3.0501 as the company signed a $16 million agreement with a major automaker to revolutionize digital car buying and leasing experience in the United States.</li>
<li>Chegg, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) gained 15% to $3.6440. Morgan Stanley analyst Josh Baer upgraded Chegg from Underweight to Equal-Weight and lowered the price target from $6.5 to $3.25.</li>
<li>8&#215;8, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) gained 13.3% to $2.8450. 8&#215;8. secured a $200 million term loan at reduced interest rate.</li>
<li>Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) gained 12.8% to $4.39.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) rose 12.8% to $1.8350. PacBio is expected to hold its quarterly conference call to discuss its second quarter financial results on Wednesday, Aug. 7.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) gained 11.8% to $1.14.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) jumped 11.8% to $10.57</li>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) surged 11.7% to $7.11.</li>
<li>ServisFirst Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFBS#NASDAQ">SFBS</a>) climbed 10.8% to $78.60 after the company reported better-than-expected second-quarter financial result. Also, Piper Sandler maintained a Neutral rating on the stock and raised its price target from $63 to $70.</li>
<li>Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) rose 7.9% to $34.54 after Starboard Value sent a letter to the company outlining initiatives for improving growth, profitability and capital allocation.</li>
<li>Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) gained 7.7% to $32.27.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) shares rose 7.3% to $68.92 after B of A Securities upgraded the stock from Neutral to Buy.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares fell 22.1% to $7.15 after jumping 54% on Monday.</li>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares declined 21.4% to $1.08. Autonomix shares jumped 130% on Monday after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Generator.</li>
<li>Zeo Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) fell 18% to $3.23.</li>
<li>Clearmind Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) fell 16.7% to $1.85. Clearmind Medicine announced the FDA clearance for IND application of MEAI-based CMND-100 oral capsule.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) declined 15.8% to $2.65.</li>
<li>Funko, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) shares fell 13.3% to $8.71.</li>
<li>Shapeways Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) fell 13.2% to $0.3010.</li>
<li>Vicinity Motor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) shares dipped 12.8% to $0.5581 after dipping 10% on Monday.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares fell 8.7% to $37.04. Trump Media &amp; Technology Group shares jumped over 31% on Monday following the attempted assassination of Donald Trump.</li>
<li>Greenpro Capital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRNQ#NASDAQ">GRNQ</a>) shares fell 8.5% to $1.08. Greenpro Capital shares surged around 35% on Monday after the company announced that its subsidiary, Green-X, secured over $100 million in digital assets.</li>
<li>Grom Social Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROM#NASDAQ">GROM</a>) shares declined 7.8% to $0.3945 after gaining around 10% on Monday.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 7.1% to $67.83 after Loop Capital downgraded the stock from Buy to Hold.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) fell 7% to $1.9150.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39792248/jim-cramer-says-if-you-sell-this-chinese-ev-stock-now-some-clown-will-be-real-posit">Jim Cramer Says If You Sell This Chinese EV Stock Now, &#8216;Some Clown&#8217; Will Be &#8216;Real Positive About It,&#8217; Wait Until &#8216;All That Stuff Happens</a><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39792248/jim-cramer-says-if-you-sell-this-chinese-ev-stock-now-some-clown-will-be-real-posit">&#8216;</a></li>
</ul>

AEON

AMIX

ARVN

ATGL

CGBS

CHGG

EGHT

EOSE

FATE

FNKO

GRNQ

GROM

KOSS

LCFY

MTCH

NAAS

NEGG

NTWK

PACB

SANA

SFBS

SHOP

SHPW

SPRC

VRPX

ZENV

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index surging more than 550 points on Tuesday.
The Dow traded up 1.41% to 40,779.92 while the NASDAQ fell 0.05% to 18,463.13. The S&amp;P 500 also rose, gaining, 0.35% to 5,651.05.
Check This Out: <a href="https://www.benzinga.com/news/24/07/39789748/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Industrials shares jumped by 2% on Tuesday.
In trading on Tuesday, information technology shares fell by 0.5%.
Top Headline
Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) reported better-than-expected second-quarter results.
The company posted second-quarter fiscal 2024 net income of $6.9 billion and EPS of 83 cents, beating the analyst consensus estimate of 80 cents.
Revenue, net of interest expense, increased 0.8% year-over-year to $25.54 billion, beating the analyst consensus estimate of $25.22 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares shot up 113% to $2.2799 after the company obtained an exclusive global license to develop, manufacture, and commercialize its Alzheimer&#8217;s drug.</li>
<li>Shares of Yoshitsu Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) got a boost, surging 89% to $0.5780 after the company reported a year-over-year increase in FY24 financial results.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares were also up, gaining 20% to $7.12 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares dropped 7% to $68.23 after Loop Capital downgraded the stock from Buy to Hold.</li>
<li>Shares of The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) were down 9% to $68.65 following second-quarter results.</li>
<li>Clearmind Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) was down, falling 15% to $1.8799. Clearmind Medicine announced the FDA clearance for IND application of MEAI-based CMND-100 oral capsule.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39789793/tecogen-and-3-other-stocks-under-5-insiders-are-buying">Tecogen And 3 Other Stocks Under $5 Insiders Are Buying</a>
Commodities In commodity news, oil traded down 1% to $81.08 while gold traded up 1.4% at $2,462.00.
Silver traded up 2% to $31.54 on Tuesday, while copper fell 1.5% to $4.4595.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.23%, Germany's DAX fell 0.32% and France's CAC 40 fell 0.64%. Spain's IBEX 35 Index fell 0.41%, while London's FTSE 100 fell 0.21%.
The ZEW Indicator of Economic Sentiment for the Eurozone fell by 7.6 points to a reading of 43.7 in July, while Eurozone posted a trade surplus of EUR 13.9 billion in May versus a year-ago gap of EUR 0.4 billion.
The ZEW Indicator of Economic Sentiment for Germany fell to 41.8 in July, recording the first decline in a year. Italy reported a trade surplus of EUR 6.43 billion in May versus a year-ago surplus of EUR 4.767 billion year.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.20%, Hong Kong's Hang Seng Index falling 1.60%, China's Shanghai Composite Index gaining 0.08% and India's S&amp;P BSE Sensex gaining 0.06%.
Economics
<ul>
<li>U.S. retail sales came in flat month-over-month for June compared to a revised 0.3% gain in the previous period.</li>
<li>Import prices came in unchanged from the prior month in June, while export prices in the U.S. declined 0.5% month-over-month in June.</li>
<li>The NAHB/Wells Fargo Housing Market Index fell by one point to a reading of 42 in July, versus market estimates of 44.</li>
<li>U.S. total business inventories increased by 0.5% month-over-month in May compared to a 0.3% gain in the earlier month.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/07/39769294/top-5-financials-stocks-that-may-collapse-this-month">Top 5 Financials Stocks That May Collapse This Month</a>

Crude Oil Down 1%; Bank of America Posts Upbeat Earnings

U.S. stocks were mostly higher, with the Dow Jones index gaining around 550 points on Tuesday.
Shares of UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) rose sharply during Tuesday's session following a <a href="https://www.benzinga.com/news/earnings/24/07/39790051/unitedhealth-q2-earnings-revenue-and-eps-beat-lifts-cyberattack-impact-estimate-reaffirms-profit-ou">second-quarter earnings beat.</a>
The company reported adjusted EPS of $6.80, up from $6.14 a year ago, beating the consensus of $6.66, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. UnitedHealth&#8217;s revenues increased nearly $6 billion (+6.4% Y/Y) to $98.86 billion, beating the consensus of $98.34 billion, led by expansion in people served domestically at Optum and UnitedHealthcare.
UnitedHealth Group shares gained 5.7% to $544.96 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Logistic Properties of the Americas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares surged 53.8% to $23.71.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares gained 24.7% to $7.39 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance.</li>
<li>Chegg, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) jumped 15% to $3.6440. Morgan Stanley analyst Josh Baer upgraded Chegg from Underweight to Equal-Weight and lowered the price target from $6.5 to $3.25.</li>
<li>8&#215;8, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) rose 13.3% to $2.8450. 8&#215;8. secured a $200 million term loan at reduced interest rate.</li>
<li>Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) climbed 12.8% to $4.39.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) gained 12.8% to $1.8350. PacBio is expected to hold its quarterly conference call to discuss its second quarter financial results on Wednesday, Aug. 7.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) rose 11.8% to $1.14.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) climbed 11.8% to $10.57</li>
<li>ServisFirst Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFBS#NASDAQ">SFBS</a>) gained 10.8% to $78.60 after the company reported better-than-expected second-quarter financial result. Also, Piper Sandler maintained a Neutral rating on the stock and raised its price target from $63 to $70.</li>
<li>Wheels Up Experience Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) rose 10.3% to $3.98.</li>
<li>Janux Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) jumped 9.7% to $47.69.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) rose 8.1% to $16.34.</li>
<li>Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) gained 7.9% to $34.54 after Starboard Value sent a letter to the company outlining initiatives for improving growth, profitability and capital allocation.</li>
<li>Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) shares climbed 7.7% to $32.27.</li>
<li>Dream Finders Homes, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFH#NYSE">DFH</a>) rose 7.5% to $30.29.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) shares gained 7.3% to $68.92 after B of A Securities upgraded the stock from Neutral to Buy.</li>
<li>Tempus AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) rose 7% to $39.15. Tempus expanded immuno-oncology portfolio with the launch of AI-enabled, multimodal immune profile algorithmic tests.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) gained 6.7% to $6.70. Newell Brands is expected to release its second quarter 2024 earnings results on Friday, July 26.</li>
<li>The Scotts Miracle-Gro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) rose 5.7% to $65.56.</li>
<li>Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) rose 5% to $43.99 following upbeat quarterly results.</li>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) gained 4.7% to $11.13.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39790965/top-3-health-care-stocks-that-should-keep-you-up-at-night-this-quarter">Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter</a></li>
</ul>

JANX

NVAX

UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America  And Other Big Stocks Moving Higher On Tuesday

WIIM

AngioDynamics shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 guidance.

AngioDynamics Forecasts Fiscal Year 2025 Adjusted EPS Of $(0.38)-$(0.42), Compared To Fiscal 2024 Pro Forma Adjusted EPS Of $(0.45) Versus Consensus Of $(0.49)

<ul>
<li>Med Tech net sales are expected to grow in the range of 10% to 12%</li>
<li>Med Device net sales are expected to grow in the range of 1% to 3%</li>
<li>Gross margin to be approximately 52% to 53%</li>
<li>Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal 2024</li>
</ul>

AngioDynamics Forecasts Fiscal Year 2025 Sales Of $282M-$288M, Representing Growth Of 4.2% – 6.4% Over Fiscal 2024 Pro Forma Revenue Of $270.7M Versus Consensus Of $287.68M

AngioDynamics Q4 2024 Adj EPS $(0.05) Beats $(0.16) Estimate, Sales $71.122M Beat $70.891M Estimate

The CE Mark for the AlphaVac F1885&nbsp;System expands treatment options for healthcare professionals in the EU by offering a tool that helps reduce thrombus burden and improve right ventricular function in patients with PE.

AngioDynamics Secures CE Mark Approval In Europe For AlphaVac F18⁸⁵ System

New data finds AlphaVac F1885 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides significant improvement in right ventricular function and reduction in clot burden

AngioDynamics APEX-AV Trial Results Assessing AlphaVac F18 System For Treatment Of Pulmonary Embolism Presented At SCAI 2024 Scientific Sessions

Although U.S. stocks closed little changed on Monday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#39;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Semtech </h3>
<ul>
<li>The Trade: Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) EVP and CFO Mark Lin <a href="https://www.benzinga.com/quote/SMTC/analyst-ratings"> acquired a total of 1,000 shares </a> an average price of $33.23. To acquire these shares, it cost around $33,232.</li>
<li>What&rsquo;s Happening: On March 28, Semtech posted a loss for the fourth quarter.</li>
<li>What Semtech Does: Semtech Corp is engaged in designing, developing, manufacturing and marketing analog and mixed-signal semiconductors, algorithms and wireless semiconductors, connectivity modules, gateways, routers and connected services for IoT.</li>
</ul>
<h3>Greif </h3>
<ul>
<li>The Trade: Greif, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gef#NYSE">GEF</a>) Executive VP &amp; General Counsel Gary R Martz acquired a total of 10,082 shares at an average price of $68.23. To acquire these shares, it cost around $687,932.</li>
<li>What&rsquo;s Happening: On Feb. 28, Greif posted upbeat quarterly earnings.</li>
<li>What Greif Does: Greif Inc is a producer of industrial packaging products and services with manufacturing facilities located in many countries.</li>
</ul>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<h3>Zumiez </h3>
<ul>
<li>The Trade: Zumiez Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zumz#NASDAQ">ZUMZ</a>) President International Adam Christopher Ellis <a href="https://www.benzinga.com/sec/insider-trades/"> bought a total of 10,000 shares </a> at an average price of $14.31. To acquire these shares, it cost around $143,100.</li>
<li>What&rsquo;s Happening: On March 20, B. Riley Securities analyst Jeff Van Sinderen maintained Zumiez with a Neutral and lowered the price target from $19 to $16.</li>
<li>What Zumiez Does: Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods.</li>
</ul>
<h3>AngioDynamics </h3>
<ul>
<li>The Trade: AngioDynamics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ango#NASDAQ">ANGO</a>) President and CEO James C Clemmer <a href="https://www.benzinga.com/sec/insider-trades/"> bought a total of 10,000 shares </a> at an average price of $6.70. The insider spent around $67,000 to buy those shares.</li>
<li>What&rsquo;s Happening: On April 4, AngioDynamics received FDA 510(k) clearance For AlphaVac F1885 System For Pulmonary Embolism.</li>
<li>What AngioDynamics Does: AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38154721/investor-optimism-improves-fear-greed-index-remains-in-greed-zone"> Investor Optimism Improves; Fear &amp; Greed Index Remains In &#39;Greed&#39; Zone </a>
&nbsp;

Long Ideas

Insider Trades

SMTC

ZUMZ

Insiders Buying Zumiez And 3 Other Stocks

AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript

AngioDynamics, Inc. 2024 Q4 - Results - Earnings Call Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
AngioDynamics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ango-stock-quote/">ANGO</a>) just reported results for the fourth quarter of 2024.<ul><li>AngioDynamics reported earnings per share of -6 cents. This was above the analyst estimate for EPS of -16 cents.</li><li>The company reported revenue of $70.98 million.</li><li>This was 0.13% better than the analyst estimate for revenue of $70.89 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/07/ango-stock-earnings-angiodynamics-for-q4-of-2024/">ANGO Stock Earnings: AngioDynamics Beats EPS, Beats Revenue for Q4 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ANGO Stock Earnings: AngioDynamics Beats EPS, Beats Revenue for Q4 2024

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC – Research Report), Argenx Se (ARGX – Research Repo...

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Argenx Se (ARGX) and AngioDynamics (ANGO)

AngioDynamics: Lumpy Progress Is Still Progress

The key to successful investing lies in choosing the right stocks, though achieving this is no small feat. Investors employ a wide array of strateg...

TipRanks 'Perfect 10' List: 2 Top-Scoring Stocks Worth Watching

Earnings week ahead: Nike, Carnival, Constellation Brands, and more

This week, several major companies will be reporting earnings. Among them are Nike (NKE), Carnival (CCL), Constellation Brands (STZ), Conagra Brand...

Options Volatility and Implied Earnings Moves This Week, September 30 – October 04, 2024

AngioDynamics Q1 2025 Earnings Preview

Here's the major earnings before the open tomorrow

AIOT

AIXI

APOG

ARGX

CALM

LEVI

LFCR

MESA

MLEC

NARI

NEOV

PAYX

POCI

STBX

TDOC

TRAK

UNFI

VLGEA

VRAR

WKEY

Press Releases

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

AngioDynamics to Participate in Upcoming Investor Conferences

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

Comments

AngioDynamics

Notizie

Ultime notizie per AngioDynamics (NASDAQ:ANGO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO